News

Filter

Current filters:

PharmaceuticalZonegran

1 to 9 of 15 results

French Transparency Commission recognizes efficacy of Eisai’s Zonegran monotherapy

French Transparency Commission recognizes efficacy of Eisai’s Zonegran monotherapy

06-10-2014

Transparency advice for Japanese pharma major Eisai’s Zonegran (zonisamide) monotherapy in the treatment…

EisaiFranceNeurologicalPharmaceuticalRegulationZonegran

Asia-Pacific epilepsy therapeutics market continues to grow as new drugs emerge

28-02-2014

The epilepsy therapeutics market value in the Asia-Pacific region - Australia, China, India and Japan…

Asia-PacificEisaiFycompaGlaxoSmithKlineKeppraMarkets & MarketingNeurologicalPharmaceuticalTrobaltUCBVimpatZonegran

FDA clears Eisai Zonegran facility in UK for US exports

FDA clears Eisai Zonegran facility in UK for US exports

15-10-2013

Eisai says the US Food and Drug Administration has approved the US supply of the epilepsy drug Zonegran…

EisaiEuropeNeurologicalNorth AmericaPharmaceuticalProductionRegulationZonegran

Eisai gains Swiss approval for Zonegran and Canadian OK for Fycompa

11-07-2013

Japanese drug major Eisai (TYO: 4205) says that Zonegran (zonisamide) has been approved by Switzerland's…

EisaiEuropeFycompaNeurologicalNorth AmericaPharmaceuticalRegulationZonegran

Eisai joins trend to enter Russian pharma market, with Halaven launch

26-03-2013

Japanese drug major Eisai (TYO; 4523, through its EMEA (Europe, Middle East and Africa) unit, has announced…

EisaiEuropeExaliefFycompaHalavenInovelonMarkets & MarketingNeurologicalOncologyPharmaceuticalZonegran

Research news: dolutegravir; TD-1211; and synaptic modulators

11-07-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) and Japanese drugmaker Shionogi (TYO: 4507) have reported…

Anti-viralsdolutegravirGalenea CorpGastro-intestinalsGlaxoSmithKlineLicensingNeurologicalPharmaceuticalRegulationResearchShionogiTD-1211TheravanceZonegran

News briefs: Priority review for ocriplasmin; Zonegran monotherapy in EU

03-07-2012

Belgium-based biopharma firm ThromboGenics (Euronext Brussels: THR) says that the US Food and Drug Administration…

EisaiEuropeNeurologicalNorth AmericaocriplasminOphthalmicsPharmaceuticalRegulationThromboGenicsZonegran

Zonegran Russian approval prompts Eisai's expansion in that market

28-06-2012

Eisai (TYO: 4523), a leading Japanese drugmaker, says it plans to expand its operations into Russia,…

EisaiEuropeFycompaHalavenMarkets & MarketingNeurologicalPharmaceuticalRegulationZonegran

1 to 9 of 15 results

Back to top